Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 15, 2022 - Issue
Submit an article Journal homepage
142
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

Wenjia Chen1 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, SingaporeView further author information
,
Mohsen Sadatsafavi2 Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0002-0419-7862View further author information
ORCID Icon,
Trung N Tran3 AstraZeneca, Gaithersburg, MD, USAView further author information
,
Ruth B Murray4 Optimum Patient Care, Cambridge, UKView further author information
,
Chong Boon Nigel Wong1 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0002-6501-8848View further author information
ORCID Icon,
Nasloon Ali4 Optimum Patient Care, Cambridge, UK;5 Observational and Pragmatic Research Institute, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0001-9585-0232View further author information
ORCID Icon,
Cono Ariti4 Optimum Patient Care, Cambridge, UK;5 Observational and Pragmatic Research Institute, Singapore, SingaporeView further author information
,
Esther Garcia Gil6 AstraZeneca, Barcelona, SpainView further author information
,
Anthony Newell5 Observational and Pragmatic Research Institute, Singapore, Singapore;7 Optimum Patient Care, Queensland, VIC, AustraliaORCID Iconhttps://orcid.org/0000-0001-6871-1392View further author information
ORCID Icon,
Marianna Alacqua8 AstraZeneca, Cambridge, UKView further author information
,
Mona Al-Ahmad9 Microbiology Department, Faculty of Medicine, Kuwait University, Al-Rashed Allergy Center, Ministry of Health, Kuwait City, KuwaitORCID Iconhttps://orcid.org/0000-0003-2950-5363View further author information
ORCID Icon,
Alan Altraja10 Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, EstoniaView further author information
,
Riyad Al-Lehebi11 Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia;12 College of Medicine, Alfaisal University, Riyadh, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0002-3232-6668View further author information
ORCID Icon,
Mohit Bhutani13 Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Western Canada, AB, CanadaView further author information
,
Leif Bjermer14 Department of Clinical Sciences, Respiratory Medicine and Allergology, Skåne University Hospital, Lund University, Lund, SwedenORCID Iconhttps://orcid.org/0000-0002-3441-8099View further author information
ORCID Icon,
Anne Sofie Bjerrum15 Department of Respiratory Medicine and Allergy, Aarhus University Hospital, Jutland, Aarhus, DenmarkView further author information
,
Arnaud Bourdin16 PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, FranceORCID Iconhttps://orcid.org/0000-0002-4645-5209View further author information
ORCID Icon,
Lakmini Bulathsinhala4 Optimum Patient Care, Cambridge, UK;5 Observational and Pragmatic Research Institute, Singapore, SingaporeView further author information
,
Anna von Bülow17 Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, DenmarkView further author information
,
John Busby18 Centre for Public Health, Queen’s University Belfast, Belfast, Northern IrelandView further author information
,
Giorgio Walter Canonica19 Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy;20 Department of Biomedical Sciences, Humanitas University, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-8467-2557View further author information
ORCID Icon,
Victoria Carter4 Optimum Patient Care, Cambridge, UK;5 Observational and Pragmatic Research Institute, Singapore, SingaporeView further author information
,
George C Christoff21 Medical University-Sofia, Faculty of Public Health, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0003-4549-7711View further author information
ORCID Icon,
Borja G Cosio22 Son Espases University Hospital-IdISBa-Ciberes, Mallorca, SpainORCID Iconhttps://orcid.org/0000-0002-6388-8209View further author information
ORCID Icon,
Richard W Costello23 Department of Respiratory Medicine, Clinical Research Centre, Smurfit Building Beaumont Hospital, RCSI, Dublin, IrelandORCID Iconhttps://orcid.org/0000-0003-1179-6692View further author information
ORCID Icon,
J Mark FitzGerald24 Department of Medicine, the University of British Columbia, Vancouver, BC, CanadaView further author information
,
João A Fonseca25 Comunity Health, Information and Decision Sciences Department (MEDCIDS) & Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine of University of Porto, Porto, PortugalView further author information
,
Kwang Ha Yoo26 KonKuk University School of Medicine in Seoul, Seoul, KoreaORCID Iconhttps://orcid.org/0000-0001-9969-2657View further author information
ORCID Icon,
Liam G Heaney27 Wellcome-Wolfson Centre for Experimental Medicine, Queen’s University Belfast, Belfast, Northern IrelandView further author information
,
Enrico Heffler19 Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy;20 Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Mark Hew28 Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, VIC, Australia;29 Public Health and Preventive Medicine, Monash University, Melbourne, VIC, AustraliaView further author information
,
Ole Hilberg30 Medical Department, Vejle University Hospital, Jutland, Vejle, DenmarkORCID Iconhttps://orcid.org/0000-0002-3075-3463View further author information
ORCID Icon,
Flavia Hoyte31 Department of Medicine, Division of Allergy and Clinical Immunology, National Jewish Health, Denver, CO, USA;32 Department of Internal Medicine, Division of Allergy & Clinical Immunology, University of Colorado School of Medicine, Aurora, CO, USAView further author information
,
Takashi Iwanaga33 Center for General Medical Education and Clinical Training, Kindai University Hospital, Osakasayama, JapanORCID Iconhttps://orcid.org/0000-0001-9155-265XView further author information
ORCID Icon,
David J Jackson34 UK Severe Asthma Network and National Registry, Guy’s and St Thomas’ NHS Trust, London, UK;35 School of Immunology & Microbial Sciences, King’s College London, London, UKView further author information
,
Rupert C Jones36 Research and Knowledge Exchange, Plymouth Marjon University, Plymouth, UKORCID Iconhttps://orcid.org/0000-0002-5463-2981View further author information
ORCID Icon,
Mariko Siyue Koh37 Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore, Singapore;38 SingHealth Duke-NUS Lung Centre, Singapore, SingaporeView further author information
,
Piotr Kuna39 Division of Internal Medicine, Asthma and Allergy Medical University of Łódź, Łódź, PolandView further author information
,
Désirée Larenas-Linnemann40 Directora Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Ciudad de México, MexicoORCID Iconhttps://orcid.org/0000-0002-5713-5331View further author information
ORCID Icon,
Sverre Lehmann41 Section of Thoracic Medicine, Department of Clinical Science, University of Bergen, Bergen, NorwayView further author information
,
Lauri A Lehtimäki42 Allergy Centre, Tampere University Hospital, Tampere, Finland;43 Faculty of Medicine and Health Technology, Tampere University, Tampere, FinlandORCID Iconhttps://orcid.org/0000-0003-1586-4998View further author information
ORCID Icon,
Juntao Lyu5 Observational and Pragmatic Research Institute, Singapore, Singapore;7 Optimum Patient Care, Queensland, VIC, AustraliaORCID Iconhttps://orcid.org/0000-0003-0465-4784View further author information
ORCID Icon,
Bassam Mahboub44 College of Medicine, University of Sharjah, Sharjah, United Arab Emirates;45 Rashid Hospital, Dubai Health Authority, Dubai, United Arab EmiratesView further author information
,
Jorge Maspero46 Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation, Buenos Aires, Argentina;47 University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine, Buenos Aires, ArgentinaView further author information
,
Andrew N Menzies-Gow48 Royal Brompton & Harefield Hospitals, London, UKView further author information
,
Concetta Sirena49 Severe Asthma Network in Italy (SANI), Milano, ItalyView further author information
,
Nikolaos Papadopoulos50 Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK;51 Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, GreeceORCID Iconhttps://orcid.org/0000-0002-4448-3468View further author information
ORCID Icon,
Andriana I Papaioannou52 2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, GreeceORCID Iconhttps://orcid.org/0000-0001-9708-3241View further author information
ORCID Icon,
Luis Pérez de Llano53 Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Lugo, Spain;54 Biodiscovery Research Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, SpainORCID Iconhttps://orcid.org/0000-0003-2652-6847View further author information
ORCID Icon,
Diahn-Warng Perng55 Division of Clinical Respiratory Physiology Chest Department, Taipei Veterans General Hospital, Taipei, Taiwan;56 COPD Assembly of the Asian Pacific Society of RespirologyHongo, Bunkyo-ku, Tokyo, JapanView further author information
,
Matthew Peters57 Department of Thoracic Medicine, Concord Hospital, Sydney, NSW, AustraliaView further author information
,
Paul E Pfeffer58 Department of Respiratory Medicine, Barts Health NHS Trust, London, UK;59 Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UKView further author information
,
Celeste M Porsbjerg17 Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, DenmarkView further author information
,
Todor A Popov60 University Hospital ”sv. Ivan Rilski”, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0001-5052-5866View further author information
ORCID Icon,
Chin Kook Rhee61 Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, South KoreaView further author information
,
Sundeep Salvi62 Pulmocare Research and Education Foundation, Pune, IndiaView further author information
,
Camille Taillé63 Department of Respiratory Diseases, Bichat Hospital, AP-HP Nord-Université de Paris, Paris, FranceView further author information
,
Christian Taube64 Department of Pulmonary Medicine, University Medical Center Essen-Ruhrlandklinik, Essen, GermanyView further author information
,
Carlos A Torres-Duque65 CINEUMO, Respiratory Research Center, Fundación Neumológica Colombiana, Bogotá, ColombiaORCID Iconhttps://orcid.org/0000-0003-0004-8955View further author information
ORCID Icon,
Charlotte S Ulrik66 Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, DenmarkORCID Iconhttps://orcid.org/0000-0001-8689-3695View further author information
ORCID Icon,
Seung Won Ra67 Department of Internal Medicine, Division of Pulmonology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South KoreaORCID Iconhttps://orcid.org/0000-0002-2458-8414View further author information
ORCID Icon,
Eileen Wang31 Department of Medicine, Division of Allergy and Clinical Immunology, National Jewish Health, Denver, CO, USA;32 Department of Internal Medicine, Division of Allergy & Clinical Immunology, University of Colorado School of Medicine, Aurora, CO, USAView further author information
,
Michael E Wechsler68 Department of Medicine, NJH Cohen Family Asthma Institute, National Jewish Health, Denver, CO, USAORCID Iconhttps://orcid.org/0000-0003-3505-2946View further author information
ORCID Icon &
David B Price4 Optimum Patient Care, Cambridge, UK;5 Observational and Pragmatic Research Institute, Singapore, Singapore;69 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9728-9992View further author information
ORCID Icon show all
Pages 1491-1510 | Received 24 Jun 2022, Accepted 23 Sep 2022, Published online: 21 Oct 2022

References

  • Reddel HK, Taylor DR, Bateman ED., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99. doi:10.1164/rccm.200801-060ST
  • Luskin AT, Antonova EN, Broder MS, et al. Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis. Clinicoecon Outcomes Res. 2016;8:641–648. doi:10.2147/CEOR.S115025
  • Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Org J. 2019;12:100007. doi:10.1016/j.waojou.2018.12.001
  • Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S176026
  • Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71:339–346. doi:10.1136/thoraxjnl-2015-207630
  • Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology. 2011;50:1982–1990. doi:10.1093/rheumatology/ker017
  • Tran TN, King E, Sarkar R, et al. Oral Corticosteroid Prescription Patterns for Asthma in France, Germany, Italy, and the United Kingdom. Eur Respir J. 2020. doi:10.1183/13993003.02363-2019
  • Tran TN, MacLachlan S, Hicks W, et al. Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma. J Allergy Clin Immunol Pract. 2021;9:338–346.e3. doi:10.1016/j.jaip.2020.06.019
  • Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. Am J Respir Crit Care Med. 2020;201:276–293. doi:10.1164/rccm.201904-0903SO
  • Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74:273–283. doi:10.1111/all.13556
  • Wang E, Wechsler ME, Tran TN, et al. Characterization of Severe Asthma Worldwide: data From the International Severe Asthma Registry. Chest. 2020;157:790–804. doi:10.1016/j.chest.2019.10.053
  • Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023–1042. doi:10.1111/all.14221
  • Krings JG, McGregor MC, Bacharier LB, et al. Biologics for Severe Asthma: treatment-Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol. 2019;7:1379–1392. doi:10.1016/j.jaip.2019.03.008
  • Porsbjerg CM, Menzies-Gow AN, Tran TN, et al. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. J Allergy Clin Immunol Pract. 2022;10:1202–1216. doi:10.1016/j.jaip.2021.12.027
  • Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J. 2018:52. doi:10.1183/13993003.01444-2018
  • FitzGerald JM, Tran TN, Alacqua M, et al. International Severe Asthma Registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020;20(1):212.
  • Bulathsinhala L, Eleangovan N, Heaney LG, et al. Development of the International Severe Asthma Registry (ISAR): a Modified Delphi Study. J Allergy Clin Immunol Pract. 2019;7:578–588.e2. doi:10.1016/j.jaip.2018.08.016
  • ISAR Study Group. International Severe Asthma Registry (ISAR): mission Statement. Chest. 2020;157:805–814.
  • Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR). Chest. 2020;157:805–814.
  • Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2018. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed September 28, 2022.
  • Heaney LG. Eosinophilic and Noneosinophilic Asthma: an Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. CHEST. 2021. doi:10.1016/j.chest.2021.04.013
  • Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc Series B. 1995;57:289–300.
  • Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes. Eur Respir J. 2021. doi:10.1183/13993003.02730-2021
  • Inselman JW, Jeffery MM, Maddux JT, et al. Trends and Disparities in Asthma Biologic Use in the United States. J Allergy Clin Immunol Pract. 2020;8:549–554.e1. doi:10.1016/j.jaip.2019.08.024
  • Bel EH, Wenzel SE, Thompson PJ, et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Eng J Med. 2014;371:1189–1197. doi:10.1056/NEJMoa1403291
  • Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma. N Eng J Med. 2017;376:2448–2458. doi:10.1056/NEJMoa1703501
  • Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Eng J Med. 2018;378:2475–2485. doi:10.1056/NEJMoa1804093
  • FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2016;388:2128–2141. doi:10.1016/S0140-6736(16)
  • Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366. doi:10.1016/S2213-2600(15)
  • Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659. doi:10.1016/S0140-6736(12)
  • Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax. 2021;76:220–227. doi:10.1136/thoraxjnl-2020-215168
  • Ortega H, Gleich G, Mayer B, et al. Reproducibility of a Single Blood Eosinophil Measurement as a Biomarker in Severe Eosinophilic Asthma. Annals ATS. 2015;12:1896–1897. doi:10.1513/AnnalsATS.201507-443LE
  • Tinoco EM, Gigante AR, Fernandes AL, et al. Impact of biologic therapy in severe asthma with nasal polyps. Eur Respir J. 2021:58. doi:10.1183/13993003.congress-2021.PA3739
  • Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650. doi:10.1016/S0140-6736(19)
  • Rogliani P, Calzetta L, Matera MG, et al. Severe Asthma and Biological Therapy: when, Which, and for Whom. Pulm Ther. 2020;6:47–66. doi:10.1007/s41030-019-00109-1
  • Matera MG, Calzetta L, Sanduzzi A, et al. Effects of neuraminidase on equine isolated bronchi. Pulm Pharmacol Ther. 2008;21:624–629. doi:10.1016/j.pupt.2008.02.003
  • d’Ancona G, Kavanagh J, Roxas C, et al. Adherence to Inhaled Corticosteroids and Clinical Outcomes in Mepolizumab Therapy for Severe Asthma. Eur Respir J. 2020. doi:10.1183/13993003.02259-2019
  • Alahmadi FH, Simpson AJ, Gomez C, et al. Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. Chest. 2021;160:53–64. doi:10.1016/j.chest.2021.02.023
  • Tiotiu A. Applying personalized medicine to adult severe asthma. Allergy Asthma Proc. 2021;42:e8–16. doi:10.2500/aap.2021.42.200100
  • Taillé C, Devillier P, Dusser D, et al. Evaluating response to biologics in severe asthma: precision or guesstimation? Respir Med Res. 2021;80:100813. doi:10.1016/j.resmer.2021.100813
  • Bossios A. Inflammatory T2 Biomarkers in Severe Asthma Patients: the First Step to Precision Medicine. J Allergy Clin Immunol Pract. 2021;9:2689–2690. doi:10.1016/j.jaip.2021.04.044

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.